[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

4D Molecular Therapeutics Inc (FDMT)

4D Molecular Therapeutics Inc (FDMT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 518,055
  • Shares Outstanding, K 52,276
  • Annual Sales, $ 85,210 K
  • Annual Income, $ -140,110 K
  • EBIT $ -180 M
  • EBITDA $ -180 M
  • 60-Month Beta 2.77
  • Price/Sales 5.50
  • Price/Cash Flow N/A
  • Price/Book 1.04

Options Overview Details

View History
  • Implied Volatility 165.03% (+27.07%)
  • Historical Volatility 66.93%
  • IV Percentile 39%
  • IV Rank 18.97%
  • IV High 545.35% on 01/08/26
  • IV Low 76.01% on 08/20/25
  • Expected Move (DTE 17) 1.17 (11.90%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 2
  • Volume Avg (30-Day) 61
  • Put/Call OI Ratio 0.41
  • Today's Open Interest 2,181
  • Open Int (30-Day) 2,050
  • Expected Range 8.69 to 11.03

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.99
  • Number of Estimates 4
  • High Estimate $-0.85
  • Low Estimate $-1.07
  • Prior Year $-0.98
  • Growth Rate Est. (year over year) -1.02%

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.07 +19.21%
on 05/19/26
11.21 -14.18%
on 05/11/26
+0.53 (+5.83%)
since 05/01/26
3-Month
7.96 +20.85%
on 03/09/26
11.21 -14.18%
on 05/11/26
-0.04 (-0.41%)
since 02/27/26
52-Week
3.55 +170.99%
on 06/02/25
12.34 -22.04%
on 10/28/25
+6.00 (+165.75%)
since 05/30/25

Most Recent Stories

More News
4DMT to Participate in Upcoming Investor Conferences

EMERYVILLE, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics...

FDMT : 9.28 (-6.36%)
4D Molecular Therapeutics Touts Rapid Phase 3 Momentum for Retinal Gene Therapy

4D Molecular Therapeutics (NASDAQ:FDMT) executives said the company is seeing strong clinical trial momentum for its lead retinal gene therapy candidate, 4D-150, as it advances through late-stage development...

FDMT : 9.28 (-6.36%)
4DMT Announces New Employment Inducement Grants

EMERYVILLE, Calif., May 15, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics...

FDMT : 9.28 (-6.36%)
4DMT Reports First Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones

4D-150 4FRONT-1 wet AMD Phase 3 randomization complete (N=523); topline data expected in H1 2027 4FRONT - 2 enrollment completion expected in H2 2026; topline data expected in H2 2027  ...

FDMT : 9.28 (-6.36%)
4DMT to Participate in Upcoming Investor Conferences

EMERYVILLE, Calif., May 04, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics...

FDMT : 9.28 (-6.36%)
4DMT Announces New Employment Inducement Grants

EMERYVILLE, Calif., April 17, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted...

FDMT : 9.28 (-6.36%)
4DMT Reports Full Year 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones

Completed enrollment in 4D-150 4FRONT-1 wet AMD Phase 3 trial within approximately 11 months, ahead of initial projections and reflecting strong interest from investigators and patients; topline data expected...

FDMT : 9.28 (-6.36%)
4DMT to Participate in Upcoming Investor Meetings

EMERYVILLE, Calif., March 16, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted...

FDMT : 9.28 (-6.36%)
4DMT to Participate in Upcoming Investor Conferences

EMERYVILLE, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted...

FDMT : 9.28 (-6.36%)
4DMT Announces New Employment Inducement Grants

EMERYVILLE, Calif., Feb. 13, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted...

FDMT : 9.28 (-6.36%)

Business Summary

4D Molecular Therapeutics Inc. is a clinical-stage gene therapy company which develops product candidates using its targeted and evolved adeno-associated viruses vectors. It offers a portfolio of gene therapy product candidates focusing on the ophthalmology, cardiology and pulmonology therapeutic areas....

See More

Key Turning Points

3rd Resistance Point 11.41
2nd Resistance Point 10.70
1st Resistance Point 10.31
Last Price 9.28
1st Support Level 9.21
2nd Support Level 8.50
3rd Support Level 8.11

See More

52-Week High 12.34
Last Price 9.28
Fibonacci 61.8% 8.98
Fibonacci 50% 7.95
Fibonacci 38.2% 6.91
52-Week Low 3.55

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.